How long does a course of Imatinib (Gleevec) usually take and analysis of treatment schedule

Imatinib (Imatinib) is an oral tyrosine kinase inhibitor mainly used to treat chronic myelogenous leukemia (CML) and certain gastrointestinal stromal tumors (GIST). It selectively inhibits BCR-ABL kinase activity and blocks abnormal signaling pathways, thereby inhibiting tumor cell proliferation and inducing apoptosis. The treatment schedule of imatinib needs to be individually adjusted based on the patient’s disease type, stage and treatment response.

For patients with chronic myeloid leukemia, it is generally recommended to start with 400mg orally administered once daily. The dose can be adjusted appropriately based on the patient's weight, tolerance and disease response. A standard course of treatment usually takes three months as an evaluation cycle. During this period, the efficacy is evaluated through hematology, molecular biology and cytology indicators, such as recovery of blood routine, decrease in BCR-ABL gene levels, etc.

During the continuous use of imatinib, patients need to be followed up regularly. In the early stage, blood routine and liver and kidney function are reviewed monthly. After the therapeutic effect is stable, the review interval can be extended to 2-3 months. Based on the evaluation results of the treatment course, the doctor may continue to maintain the original dose, adjust the dose, or extend the course of treatment, especially after the molecular remission (MR) is achieved. In order to consolidate the curative effect, the course of treatment usually needs to be continued for several years or even long-term maintenance.

For patients with gastrointestinal stromal tumors, the course of imatinib treatment is usually adjuvant therapy for more than one year after surgery to reduce the risk of recurrence. The treatment schedule also needs to be individually adjusted based on the patient's postoperative recovery, drug tolerance, and tumor risk stratification. In summary, the imatinib regimen emphasizes continued medication, regular monitoring, and individualized management to maximize treatment effects and reduce the risk of relapse or drug resistance.

Reference materials:https://www.drugs.com/